Adicet Bio Inc.
| NASDAQ: ACET | Healthcare / Biotechnology / USA |
| 1.29 | -0.0100 | -0.77% | Vol 149.41K | 1Y Perf -91.48% |
| Oct 4th, 2023 16:00 DELAYED |
| BID | 1.26 | ASK | 1.30 | ||
| Open | 1.29 | Previous Close | 1.30 | ||
| Pre-Market | - | After-Market | 1.30 | ||
| - - | 0.01 0.78% |
| Target Price | 28.83 | Analyst Rating | Moderate Buy 1.75 | |
| Potential % | 2.13K | Finscreener Ranking | ★★★★+ 56.41 | |
| Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | ★★★★ 56.61 | |
| Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ★★★★+ 60.56 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | ★ — - | |
| Price Range Ratio 52W % | 0.10 | Earnings Rating | Neutral | |
| Market Cap | 55.56M | Earnings Date | 14th Nov 2023 | |
| Alpha | -0.04 | Standard Deviation | 0.26 | |
| Beta | 2.03 |
Today's Price Range 1.261.30 | 52W Range 1.2721.87 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -9.15% | ||
| 1 Month | -30.65% | ||
| 3 Months | -59.18% | ||
| 6 Months | -76.46% | ||
| 1 Year | -91.48% | ||
| 3 Years | -89.28% | ||
| 5 Years | -42.67% | ||
| 10 Years | -91.46% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | - | |||
ROE last 12 Months | -22.22 | |||
ROA (5Y Avg) | - | |||
ROA last 12 Months | -19.48 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -19.85 | |||
Return on invested Capital Q | -7.08 | |||
Return on invested Capital Y | -27.18 | |||
Assets Turnover | 0.10 | |||
Receivables Turnover | 105.80 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -5.80 | ||||
| 1.13 | ||||
| 5.98 | ||||
| - | ||||
| -9.90 | ||||
| -1.01 | ||||
| 1.20 | ||||
| 7.41 | ||||
| 98.13M | ||||
| Forward PE | -0.57 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 16.40 | ||||
| 16.60 | ||||
| 0.06 | ||||
| 0.07 | ||||
| -704.60 | ||||
| Leverage Ratio | 1.10 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| -182.70 | ||||
| -176.60 | ||||
| - | ||||
| -76.31 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 24.99M | ||||
| 1.28 | ||||
| 112.45 | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | 123.00 |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2023 | -0.68 | -0.75 | -10.29 |
| Q01 2023 | -0.74 | -0.72 | 2.70 |
| Q04 2022 | -0.56 | -0.72 | -28.57 |
| Q03 2022 | -0.56 | -0.53 | 5.36 |
| Q02 2022 | -0.45 | -0.56 | -24.44 |
| Q01 2022 | -0.07 | 0.10 | 242.86 |
| Q04 2021 | -0.44 | -0.47 | -6.82 |
| Q03 2021 | -0.38 | -0.44 | -15.79 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 9/2023 QR | -0.73 | 1.35 | Positive |
| 12/2023 QR | -0.70 | -29.63 | Negative |
| 12/2023 FY | -2.93 | -4.27 | Negative |
| 12/2024 FY | -2.40 | 8.05 | Positive |
| Next Report Date | 14th Nov 2023 |
| Estimated EPS Next Report | -0.73 |
| Estimates Count | 5 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 149.41K |
| Shares Outstanding | 43.07K |
| Shares Float | 22.83M |
| Trades Count | 1.51K |
| Dollar Volume | 192.13K |
| Avg. Volume | 465.03K |
| Avg. Weekly Volume | 416.24K |
| Avg. Monthly Volume | 430.57K |
| Avg. Quarterly Volume | 548.29K |
Adicet Bio Inc. (NASDAQ: ACET) stock closed at 1.29 per share at the end of the most recent trading day (a -0.77% change compared to the prior day closing price) with a volume of 149.41K shares and market capitalization of 55.56M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 0 people. Adicet Bio Inc. CEO is Chen Schor.
The one-year performance of Adicet Bio Inc. stock is -91.48%, while year-to-date (YTD) performance is -85.57%. ACET stock has a five-year performance of -42.67%. Its 52-week range is between 1.27 and 21.87, which gives ACET stock a 52-week price range ratio of 0.10%
Adicet Bio Inc. currently has a PE ratio of -5.80, a price-to-book (PB) ratio of 1.13, a price-to-sale (PS) ratio of 5.98, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -19.48%, a ROC of -19.85% and a ROE of -22.22%. The company’s profit margin is -76.31%, its EBITDA margin is -176.60%, and its revenue ttm is $24.99 Million , which makes it $1.28 revenue per share.
Of the last four earnings reports from Adicet Bio Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.73 for the next earnings report. Adicet Bio Inc.’s next earnings report date is 14th Nov 2023.
The consensus rating of Wall Street analysts for Adicet Bio Inc. is Moderate Buy (1.75), with a target price of $28.83, which is +2 134.88% compared to the current price. The earnings rating for Adicet Bio Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Adicet Bio Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of 123.00%.
Adicet Bio Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 12.36, ATR14 : 0.13, CCI20 : -130.15, Chaikin Money Flow : -0.48, MACD : -0.18, Money Flow Index : 35.88, ROC : -23.98, RSI : 27.08, STOCH (14,3) : 5.16, STOCH RSI : 0.00, UO : 30.08, Williams %R : -94.84), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Adicet Bio Inc. in the last 12-months were: Advisors LLC. Orbimed (Buy at a value of $1 828 750), Blake Aftab (Option Excercise at a value of $25 003), Blake Aftab (Sold 16 680 shares of value $302 905 ), Carl Gordon (Buy at a value of $1 828 750), Chen Schor (Sold 95 268 shares of value $1 839 448 ), Don Healey (Sold 10 467 shares of value $83 476 ), DUBIN STEVE (Buy at a value of $12 000), Healey Don (Sold 15 000 shares of value $117 841 )
Adicet Bio Inc.
Adicet Bio Inc is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. The company is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients.
CEO: Chen Schor
Telephone: +1 857 315-5528
Address: 200 Construction Drive, Menlo Park 94025, CA, US
Number of employees: 0
